HESTERBIO
Hester Biosciences Limited (HESTERBIO) Stock Analysis
Hester Biosciences Limited is an Indian animal health company manufacturing poultry and livestock vaccines. It supplies biological products to farmers and integrators in India and Africa. The company operates vaccine plants with global partnerships. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹2,058.70
-3.20% 1W | +24.40% 52W
Market Cap
1.8k CR
P/E Ratio
12.8
52W High
₹2683.6
52W Low
₹1239.3
Div. Yield
0.53%
Beta
0.4
50 DMA
₹2319.8
200 DMA
₹1873.1
Profit Margin
41.6%
Inst. Own.
0.2%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 88 | 70 | 67 | 79 | 82 | 84 | 63 | 82 | 84 | 71 | 77 | 100 | 77 |
| Expenses | 73 | 57 | 57 | 63 | 65 | 65 | 58 | 63 | 61 | 59 | 60 | 66 | 54 |
| Operating Profit | 14 | 13 | 10 | 16 | 18 | 19 | 5 | 19 | 23 | 12 | 18 | 34 | 23 |
| OPM % | 16% | 19% | 15% | 20% | 21% | 23% | 8% | 23% | 27% | 17% | 23% | 34% | 29% |
| Other Income | 3 | 6 | 2 | 5 | 2 | 3 | 9 | -6 | 3 | 12 | 2 | 2 | 89 |
| Interest | 3 | 8 | 2 | 7 | 5 | 6 | -4 | 6 | 2 | 2 | 2 | 5 | 3 |
| Depreciation | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 7 |
| Profit before tax | 9 | 7 | 6 | 10 | 11 | 12 | 13 | 4 | 20 | 17 | 14 | 25 | 102 |
| Tax % | 25% | 40% | 37% | 35% | 29% | 29% | 15% | 59% | 14% | 16% | 31% | 34% | 5% |
| Net Profit | 7 | 4 | 4 | 6 | 7 | 8 | 11 | 2 | 17 | 14 | 9 | 17 | 97 |
| EPS in Rs | 6.90 | 4.81 | 4.68 | 5.82 | 7.45 | 9.64 | 13.71 | 1.52 | 19.33 | 16.99 | 10.31 | 18.78 | 114.00 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 90 | 101 | 123 | 136 | 178 | 183 | 214 | 235 | 266 | 305 | 311 | 333 | 326 |
| Expenses | 64 | 67 | 82 | 89 | 110 | 128 | 146 | 175 | 215 | 251 | 250 | 246 | 239 |
| Operating Profit | 25 | 34 | 41 | 47 | 68 | 55 | 69 | 60 | 51 | 54 | 62 | 87 | 87 |
| OPM % | 28% | 34% | 33% | 35% | 38% | 30% | 32% | 26% | 19% | 18% | 20% | 26% | 27% |
| Other Income | 3 | 1 | 0 | 3 | 7 | 6 | 1 | 14 | 20 | 15 | 8 | 19 | 105 |
| Interest | 5 | 4 | 4 | 4 | 7 | 7 | 7 | 4 | 9 | 20 | 13 | 11 | 12 |
| Depreciation | 6 | 6 | 7 | 10 | 12 | 13 | 13 | 17 | 21 | 17 | 17 | 19 | 22 |
| Profit before tax | 18 | 25 | 31 | 36 | 57 | 41 | 50 | 54 | 40 | 32 | 40 | 76 | 157 |
| Tax % | 26% | 23% | 26% | 36% | 28% | 25% | 31% | 26% | 30% | 34% | 27% | 24% | |
| Net Profit | 13 | 19 | 23 | 23 | 41 | 31 | 35 | 39 | 28 | 21 | 29 | 57 | 137 |
| EPS in Rs | 15.99 | 22.57 | 27.68 | 30.12 | 48.87 | 34.29 | 40.47 | 46.22 | 31.30 | 22.21 | 32.31 | 65.41 | 160.08 |
| Dividend Payout % | 19% | 18% | 19% | 33% | 23% | 19% | 25% | 22% | 26% | 27% | 22% | 17% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 8.0% | 9.0% | 13.0% |
| Profit CAGR | 26.0% | 8.0% | 11.0% |
Shareholding Pattern
Promoters53.73%
FIIs0.51%
DIIs0.02%
Public45.73%
Promoters53.73%
FIIs0.53%
Public45.73%
Promoters53.73%
FIIs0.52%
DIIs0.01%
Public45.75%
Promoters53.73%
FIIs0.38%
Public45.88%
Promoters53.73%
FIIs0.31%
Public45.95%
Promoters53.73%
FIIs0.45%
Public45.81%
Promoters53.73%
FIIs0.43%
Public45.84%
Promoters53.73%
FIIs0.87%
DIIs0.02%
Public45.38%
Promoters53.73%
FIIs0.38%
Public45.88%
Promoters53.73%
FIIs0.31%
Public45.95%
HESTERBIO
Holdings Analysis
Key strengths & risk signals
76
Overall
71
Fundamental
81
Technical
Risks (3)
TOO MUCH PUBLIC HOLDING! 45.82% public ownership - higher volatility risk.
RECOVERY MODE! Current price (2058.7) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.2% (1 week), 11.4% (1 month), 2.9% (3 months).
Strengths (4)
EXCELLENT EFFICIENCY! 41.6% profit margin - company keeps strong profits.
BULLISH TREND! 50-day average (2319.8) is above 200-day average (1873.1) - positive signal.
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 12,324 vs down days: 3,657. Ratio: 3.37x
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
Fundamental & Technical Analysis
76Overall
71Fundamental
81Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 7.7% (MODERATE, 8/15). Profit CAGR: 27.8% (EXCELLENT, 15/15).
Profit Margin
10/10
EXCELLENT EFFICIENCY! 41.6% profit margin - company keeps strong profits.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.46 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.53% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 45.82% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2319.8) is above 200-day average (1873.1) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (2058.7) above 200-day but below 50-day.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
8/10
GOOD YEAR! Stock gained 24.4% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 12,324 vs down days: 3,657. Ratio: 3.37x
RSI
4/5
APPROACHING OVERSOLD! RSI at 36.0 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 56.7% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.2% (1 week), 11.4% (1 month), 2.9% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
HESTERBIO
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-01 | Concall PDF | |
| Q4FY262026-05-18 | Concall PDF | |
| Q3FY262026-02-02 | Concall PDF | |
| Q2FY262025-11-14 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HESTERBIO | ₹2,058.70 | 12.8 | 41.6% | 7.7% | 27.8% | +24.4% | 76 | BOUNCE FROM SUPPORT | +491.5% | +506.3% | -8.2% | -22.9% |
| WINDLAS | ₹949.20 | 30.4 | 7.1% | 20.7% | 16.0% | +11.7% | 75 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
| BETA | ₹1,950.20 | 28.7 | 11.1% | 19.2% | 10.5% | +13.7% | 67 | APPROACHING SUPPORT | +35.0% | +75.6% | +25.2% | +33.5% |
| FERMENTA | ₹517.50 | 25 | 11.7% | 14.5% | – | +24.5% | 65 | CONSOLIDATING DOWN | -55.5% | -49.5% | -10.6% | +0.2% |
| JAGSNPHARM | ₹225.60 | 33.6 | 15.5% | 6.7% | 17.3% | +6.6% | 72 | BOUNCE FROM SUPPORT | +22.2% | +50.0% | +8.7% | +28.0% |
| AHCL | ₹28.10 | 41.3 | 14.0% | 15.1% | 69.8% | +107.2% | 81 | BREAKOUT | +91.4% | -36.2% | +163.1% | +72.1% |
| INDOCO | ₹230.70 | 699.1 | 0.3% | 3.0% | – | -14.2% | 54 | BREAKDOWN | -281.6% | -400.9% | +8.2% | +2.3% |
| AMRUTANJAN | ₹508.90 | 27.3 | 10.6% | 9.9% | 13.3% | -26.2% | 54 | APPROACHING RESISTANCE | -47.0% | -72.8% | +9.6% | -31.2% |
Data from TradeAlone · Updated daily
